Armadin (mexidol) solution for injections 50 mg/ml. ampoules 2 ml. №10

$79.00

Manufacturer: Ukraine

Armadin (mexidol) solution is indicated for:

  • Goctpi disorders of cerebral circulation;
  • craniocerebral trauma; consequences of craniocerebral injuries;
  • encephalopathy;
  • cardiopsychoneurosis;
  • mild cognitive impairment of atherosclerotic origin;
  • anxiety disorders in neurotic and neurosis-like conditions;
  • acute myocardial infarction (from the first day), as part of complex therapy;
  • primary open-angle glaucoma of different stages as part of complex therapy;
  • relief of withdrawal symptoms in alcoholism with a predominance of neurosis-like and neurocirculatory disorders;
  • acute intoxication with antipsychotics;
  • acute purulent-inflammatory processes in the abdominal cavity (acute necrotizing pancreatitis, peritonitis) as part of complex therapy.

Category:

Description

Ingredients

active ingredient : mexidol;

1 ampoule contains 2-ethyl-6-methyl-3-hydroxypyridine succinate 100 mg;

excipients : water for injection.

Dosage form

Injection.

Basic physical and chemical properties : colorless or slightly colored transparent liquid.

Pharmacotherapeutic group

Drugs affecting the nervous system. ATC code N07X.

Pharmacodynamics

Armadin (mexidol) is an inhibitor of free radical processes, a membrane protector, has antihypoxic, stress-protective, nootropic, anticonvulsant and anxiolytic effects. The drug increases the body’s resistance to the action of various damaging factors, to oxygen pathological conditions (shock, hypoxia and ischemia, cerebrovascular accident, intoxication with alcohol and antipsychotics (neuroleptics)).

The drug improves cerebral metabolism and blood supply to the brain, microcirculation and rheological properties of blood, reduces platelet aggregation. Stabilizes the membrane structures of blood cells (erythrocytes and platelets) during hemolysis. It has a hypolipidemic effect, reduces the content of total cholesterol and low density lipoproteins (LDL). Reduces enzymatic toxemia and endogenous intoxication in acute pancreatitis.

The mechanism of action of the drug is due to its antioxidant and membrane-protective action. It inhibits lipid peroxidation, increases the activity of superoxide dismutase, increases the lipid-protein ratio, reduces the viscosity of the membrane, increases its fluidity. Modulates the activity of membrane-binding enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, γ-aminobutyric acid (GABA), acetylcholine), which enhances their ability to bind to the organization of neurotransmitters and improve synaptic transmission. Armadin increases the content of dopamine in the brain.

Armadin (mexidol) normalizes metabolic processes in the ischemic myocardium, reduces the necrosis zone, restores and improves the electrical activity and contractility of the myocardium, and also increases coronary blood flow in the ischemic zone, reduces the consequences of reperfusion syndrome in acute coronary heart disease. Increases antianginal activity of nitropreparations. Armadin contributes to the preservation of retinal ganglion cells and optic nerve fibers in progressive neuropathy, the consequences of which are chronic ischemia and hypoxia. Improves the functional activity of the retina and optic nerve, increasing visual acuity.

Pharmacokinetics

When administered intramuscularly, the drug is determined in the blood plasma within 4 hours after administration. The time to reach the maximum concentration is 0.45-0.5 hours. The maximum concentration at doses of 400–500 mg is 3.5–4.0 μg / ml. Armadin quickly passes from the bloodstream to organs and tissues and is quickly eliminated from the body. The drug is excreted from the body with urine, mainly in the glucuron-conjugated form and in small amounts – unchanged.

Indications

  • Goctpi disorders of cerebral circulation;
  • craniocerebral trauma; consequences of craniocerebral injuries;
  • encephalopathy;
  • cardiopsychoneurosis;
  • mild cognitive impairment of atherosclerotic origin;
  • anxiety disorders in neurotic and neurosis-like conditions;
  • acute myocardial infarction (from the first day), as part of complex therapy;
  • primary open-angle glaucoma of different stages as part of complex therapy;
  • relief of withdrawal symptoms in alcoholism with a predominance of neurosis-like and neurocirculatory disorders;
  • acute intoxication with antipsychotics;
  • acute purulent-inflammatory processes in the abdominal cavity (acute necrotizing pancreatitis, peritonitis) as part of complex therapy.

Contraindications

Hypersensitivity to Armadin (mexidol), acute liver or kidney failure. The period of pregnancy or breastfeeding. Childhood.

Dosage and administration

Armadin (mexidol) is appointed intramuscularly or intravenously (stream or drip). Doses are selected individually. With the infusion method, Armadin (mexidol) should be diluted in a 0.9% solution of sodium chloride (200 ml). Start treatment in adults with a dose of 50-100 mg 1-3 times a day, gradually increasing the dose until a therapeutic effect is obtained. Rapidly inject armadin slowly over 5-7 minutes, drip – at a rate of 40-60 drops per 1 minute. The maximum daily dosage should not exceed 800 mg.

In case of acute disorders of cerebral circulation, Armadin (mexidol) is prescribed in complex therapy for the first 2–4 days intravenously by stream or drip for adults, 200–300 mg 1 time per day, then intramuscularly, 100 mg 3 times per day. The duration of treatment is 10-14 days.

In case of traumatic brain injury and the consequences of traumatic brain injuries, ARMADIN should be used for 10-15 days by intravenous drip, 200-500 mg 2-4 times a day.

With dyscirculatory encephalopathy in the decompensation phase, Armadin should be administered intravenously by stream or drip at a dose of 100 mg 2-3 times a day for 14 days. Then the drug is administered intramuscularly at 100 mg / day for the next 2 weeks.

For course prevention of dyscirculatory encephalopathy, the drug is administered to adults intramuscularly at 100 mg 2 times a day for 10-14 days.

For mild cognitive impairment in elderly patients and in anxiety states, the drug should be administered intramuscularly at a dose of 100-300 mg / day for 14-30 days.

In acute myocardial infarction, as part of complex therapy, ARMADIN should be administered intravenously or intramuscularly for 14 days, against the background of traditional therapy for myocardial infarction, including nitrates, β-blockers, angiotensin-converting enzyme inhibitors and AP, symptomatic agents according to indications In the first 5 days, to achieve maximum effect , preferably intravenous administration of the drug Armadin, intramuscular administration is possible in the next 9 days. Intravenous administration of the drug ARMADIN should be carried out by drip infusion, slowly (to avoid side effects), in 0.9% sodium chloride solution or 5% glucose solution in a volume of 100-150 ml for 30-90 minutes. If necessary, slow jet administration of the drug is possible for at least 5 minutes.

The introduction of the drug ARMADIN (intravenous or intramuscular) is carried out 3 times a day, every 8 hours. The daily therapeutic dose is 6–9 mg per kilogram of body weight per day, a single dose is 2–3 mg/kg of body weight. The maximum daily dose should not exceed 800 mg, a single dose – 250 mg.

In case of open-angle glaucoma of different stages, as part of complex therapy, Armadin is administered intramuscularly at 100-300 mg / day, 1-3 times a day, for 14 days.

With alcohol withdrawal syndrome, Armadin is administered at a dose of 100-200 mg intramuscularly 2-3 times a day or intravenously drip 1-2 times a day for 5-7 days.

In acute intoxication with antipsychotic drugs for adults, the drug is administered intravenously at a dose of 50-300 mg / day for 7-14 days.

In acute purulent-inflammatory processes of the abdominal cavity (acute necrotizing pancreatitis, peritonitis), the drug should be prescribed on the first day, both in the preoperative and postoperative period. Doses depend on the form and severity of the disease, the prevalence of the process, variants of the clinical course. The drug should be discontinued gradually only after a persistent positive clinical and laboratory effect.

In acute edematous (interstitial) pancreatitis, Armadin is prescribed to adults at 100 mg 3 times a day intravenously (in 0.9% sodium chloride solution) and intramuscularly. Mild severity of necrotizing pancreatitis: 100-200 mg 3 times a day intravenously drip (in 0.9% sodium chloride solution) and intramuscularly. Moderate severity: adults – 200 mg 3 times a day intravenously (in 0.9% sodium chloride solution).

Severe course : in a pulse dosage of 800 mg on the first day with a double injection, then – 300 mg 2 times a day with a gradual decrease in the daily dose.

Very severe course : at an initial dose of 800 mg / day until persistent relief of the manifestation of pancreatogenic shock, after stabilization of the condition – 300-400 mg 2 times a day intravenously (in 0.9% sodium chloride solution) with a gradual decrease in the daily dose.